



Ref: BHL/ STEX 61/ 2025-26

Date: January 16, 2026

<b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	<b>National Stock Exchange of India Limited</b> 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
<b>Scrip Code: 539872</b>	<b>Symbol: BAJAJHCARE</b>

**Sub: Press Release for the Quarter ended December 31, 2025**

Dear Sir/Madam,

Please find enclosed herewith Press Release on financial results of the Company for the quarter ended December 31, 2025.

Kindly take the same on record.

Thanking you.

Yours faithfully,

**For and on behalf of Bajaj Healthcare Limited**

**Monica Tanwar**  
**Company Secretary & Compliance Officer**

***Encl: As above***

**BAJAJ HEALTHCARE LTD**

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : [www.bajajhealth.com](http://www.bajajhealth.com)

CIN No.: L99999MH1993PLC072892



## Investor Release

### Bajaj Healthcare Limited reports Q3 & 9M FY26 results (Strong Export Momentum Drives 31% Revenue Growth)

**Mumbai, 16<sup>th</sup> Jan 2026:** Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its financial results for the quarter and nine months ended 31<sup>st</sup> Dec 2025.

#### Key Financial Highlights

Particulars (Rs. Mn)	Q3 FY26	Q3 FY25	Y-o-Y	9M FY26	9M FY25	Y-o-Y
Revenue from Operations	1,612.2	1,227.9	<b>31.3%</b>	4,579.7	3,881.3	<b>18.0%</b>
EBITDA	323.3	240.1	<b>34.6%</b>	863.2	765.0	<b>12.8%</b>
EBITDA Margin (%)	19.8%	19.2%		18.7%	19.4%	
PAT from Cont. Operations	161.0	149.7	<b>7.6%</b>	407.2	313.4	<b>30.0%</b>
PAT Margin (Cont. Operations)	9.9%	12.0%		8.8%	8.0%	
Profit for the period	156.7	117.2	<b>33.7%</b>	386.2	283.2	<b>36.4%</b>
Profit for the period(%)	9.6%	9.4%		8.4%	7.2%	

#### Revenue Breakup

Particulars (Rs. Mn)	Q3 FY26	Q3 FY25	Y-o-Y	9M FY26	9M FY25	Y-o-Y
API (Domestic)	838.5	727.2	<b>15.3%</b>	2327.2	2375.7	<b>-2.0%</b>
API (Exports)	486.8	232.0	<b>109.8%</b>	1496.0	833.9	<b>79.4%</b>
Formulations	287.0	268.8	<b>6.8%</b>	756.5	671.8	<b>12.6%</b>

#### Key Business Highlights

- ✓ Bajaj Healthcare became the first Indian company to receive CDSCO approval for Phase III clinical trials and bioequivalence studies of Suvorexant Tablets, reinforcing our drug development expertise and specialty pipeline
- ✓ Successfully launched Magnesium L-Threonate (Magtein) in India through our collaboration with Threotech LLC. Backed by our strong domestic presence and manufacturing expertise, this milestone expands our CNS portfolio and reinforces our position as a trusted partner to global innovators
- ✓ Filed 9 DMFs throughout the quarter, taking cumulative DMF filings to 69. These filings will support future commercial supply in the regulated markets and strengthen our expansion into high-value segments



- ✓ Cumulative CEP filings stand at ten, with eight approved and two under review; two additional CEPs currently in progress, further strengthening our position in regulated EU and UK markets.

**Commenting on the Results, Mr. Anil Jain – Managing Director said,**

*“Amid global volatility and geopolitical uncertainty, our Q3 FY26 results highlight the resilience of our operations and disciplined execution. Revenue grew 31% year-on-year, supported by a robust 35% increase in EBITDA. A key driver of this performance was the strong growth in API exports, which more than doubled compared to last year. This momentum has translated into a 30% increase in PAT for the nine months ended December 2025, reaffirming our ability to scale rapidly in regulated markets.*

*Our domestic API business recorded growth of 15%. While pricing pressure persists across the industry, our continued focus on driving steady volume growth is yielding results. The increased focus on the formulations business is contributing meaningfully and is scaling well. Our CDMO business is also gaining traction with supplies ramping up significantly, underscoring our ability to integrate seamlessly with global innovators, while building a scalable and diversified growth engine for the future.*

*We continue to advance our CNS portfolio, with recently secured CDSCO approval to conduct trials for Suvorexant and ongoing Phase III trials for Cenobamate. With the launch of Magtein this quarter, we have further strengthened our offerings in the segment. Other molecules are also scaling up, adding depth to the portfolio. Together, these initiatives highlight our focus on high-potential therapeutic areas and reinforce our commitment to addressing unmet global needs.*

*On the regulatory front, we continue to strengthen our global compliance framework and advance product registrations across key geographies. Our focus remains on expanding our presence in regulated markets and aligning our pipeline with high-value therapeutic areas that offer long-term growth potential.*

*As we look ahead, our business mix will increasingly shift toward exports anchored by our strong API foundation and growing credibility in regulated markets. We remain focused on sustaining cost competitiveness while securing key approvals that broaden our global reach. With continued investments in R&D, ongoing capex, and the expertise of our management team, we are confident of achieving sustainable and scalable growth. We remain committed to creating long-term value for the healthcare ecosystem and all stakeholders.”*

**About Bajaj Healthcare Ltd:**

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.



## Contact Details

Bajaj Healthcare Ltd	Investor Relations: MUFG Intime India Pvt. Ltd.
CIN: L99999MH1993PLC072892	Name: Ms. Prachi Ambre/ Mr. Irfan Raeen
Name: Mr. Anil Jain, MD	Email: <a href="mailto:prachi.ambre@in.mpms.mufg.com">prachi.ambre@in.mpms.mufg.com</a> / <a href="mailto:irfan.raeen@in.mpms.mufg.com">irfan.raeen@in.mpms.mufg.com</a>
Email: <a href="mailto:investors@bajajhealth.com">investors@bajajhealth.com</a>	Meeting Request Link – <a href="#">Link</a>

## Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downturn in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.